May 20, 2021 06:54 AM EDTUpdated 07:15 AM
R&D

Eli Lil­ly wraps up fifth and fi­nal tirzepatide PhI­II tri­al, claim­ing a win over Sanofi's Lan­tus. The FDA awaits

Max Gelman

Senior Editor

Eli Lil­ly has long been test­ing its ex­per­i­men­tal tirzepatide can­di­date in di­a­betes, look­ing to see whether or not it can take over Trulic­i­ty’s di­a­betes man­tle …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

Bris­tol My­ers re­veals more job cuts in New Jer­sey

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Mer­ck halts Phase 3 tri­al with PAH drug Win­re­vair fol­low­ing pos­i­tive in­ter­im da­ta 

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Cas­sa­va shares plunge as con­tro­ver­sial Alzheimer’s drug fails Phase 3 tri­al

A service from the Financial Times